Review
Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part II: Photodynamic Therapy, Vismodegib, Cetuximab, Intralesional Methotrexate, and Radiotherapy
Resistencias al tratamiento no quirúrgico en cáncer cutáneo no melanoma. Parte II: terapia fotodinámica, vismodegib, cetuximab, metotrexato intralesional y radioterapia
Leído
6539
Vecesse ha leído el artículo
2229
Total PDF
4310
Total HTML
Compartir estadísticas
array:24 [ "pii" => "S1578219016302219" "issn" => "15782190" "doi" => "10.1016/j.adengl.2016.08.017" "estado" => "S300" "fechaPublicacion" => "2016-11-01" "aid" => "1436" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2016;107:740-50" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1278 "formatos" => array:3 [ "EPUB" => 48 "HTML" => 842 "PDF" => 388 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731016301533" "issn" => "00017310" "doi" => "10.1016/j.ad.2016.04.020" "estado" => "S300" "fechaPublicacion" => "2016-11-01" "aid" => "1436" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2016;107:740-50" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 602 "formatos" => array:3 [ "EPUB" => 2 "HTML" => 459 "PDF" => 141 ] ] "es" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Revisión</span>" "titulo" => "Resistencias al tratamiento no quirúrgico en cáncer cutáneo no melanoma. Parte II: terapia fotodinámica, vismodegib, cetuximab, metotrexato intralesional y radioterapia" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:3 [ 0 => "es" 1 => "es" 2 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "740" "paginaFinal" => "750" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part II: Photodynamic Therapy, Vismodegib, Cetuximab, Intralesional Methotrexate, and Radiotherapy" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0020" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 944 "Ancho" => 1333 "Tamanyo" => 99295 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "T. Gracia-Cazaña, N. Salazar, A. Zamarrón, M. Mascaraque, S.R. Lucena, Á. Juarranz" "autores" => array:6 [ 0 => array:2 [ "nombre" => "T." "apellidos" => "Gracia-Cazaña" ] 1 => array:2 [ "nombre" => "N." "apellidos" => "Salazar" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Zamarrón" ] 3 => array:2 [ "nombre" => "M." "apellidos" => "Mascaraque" ] 4 => array:2 [ "nombre" => "S.R." "apellidos" => "Lucena" ] 5 => array:2 [ "nombre" => "Á." "apellidos" => "Juarranz" ] ] ] ] "resumen" => array:1 [ 0 => array:3 [ "titulo" => "Graphical abstract" "clase" => "graphical" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0020"></elsevierMultimedia></p></span>" ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219016302219" "doi" => "10.1016/j.adengl.2016.08.017" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219016302219?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731016301533?idApp=UINPBA000044" "url" => "/00017310/0000010700000009/v1_201611020109/S0001731016301533/v1_201611020109/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219016301871" "issn" => "15782190" "doi" => "10.1016/j.adengl.2016.08.002" "estado" => "S300" "fechaPublicacion" => "2016-11-01" "aid" => "1461" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2016;107:751-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 787 "formatos" => array:3 [ "EPUB" => 47 "HTML" => 555 "PDF" => 185 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "The Spanish Psoriasis Patients’ Association According to Its Members: Cross-Sectional Descriptive Study of Members’ Opinions of the Association's Functions" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "751" "paginaFinal" => "757" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Función y respaldo a la asociación de pacientes con psoriasis en España según sus miembros: estudio descriptivo transversal" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. González-de Paz, M. Ribera, J. Gratacós-Masmitjà, S. Ros, C. Blanch Mur, S. Alfonso-Zamora" "autores" => array:6 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "González-de Paz" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Ribera" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Gratacós-Masmitjà" ] 3 => array:2 [ "nombre" => "S." "apellidos" => "Ros" ] 4 => array:2 [ "nombre" => "C." "apellidos" => "Blanch Mur" ] 5 => array:2 [ "nombre" => "S." "apellidos" => "Alfonso-Zamora" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731016302320" "doi" => "10.1016/j.ad.2016.06.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731016302320?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219016301871?idApp=UINPBA000044" "url" => "/15782190/0000010700000009/v1_201611010039/S1578219016301871/v1_201611010039/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219016302207" "issn" => "15782190" "doi" => "10.1016/j.adengl.2016.08.016" "estado" => "S300" "fechaPublicacion" => "2016-11-01" "aid" => "1434" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "ssu" "cita" => "Actas Dermosifiliogr. 2016;107:730-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1931 "formatos" => array:3 [ "EPUB" => 53 "HTML" => 1553 "PDF" => 325 ] ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part I: Topical Treatments" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:3 [ 0 => "en" 1 => "en" 2 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "730" "paginaFinal" => "739" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Resistencias al tratamiento no quirúrgico en cáncer cutáneo no melanoma. Parte I: tratamientos tópicos" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0025" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 1008 "Ancho" => 1333 "Tamanyo" => 74816 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "T. Gracia-Cazaña, S. González, Y. Gilaberte" "autores" => array:3 [ 0 => array:2 [ "nombre" => "T." "apellidos" => "Gracia-Cazaña" ] 1 => array:2 [ "nombre" => "S." "apellidos" => "González" ] 2 => array:2 [ "nombre" => "Y." "apellidos" => "Gilaberte" ] ] ] ] "resumen" => array:1 [ 0 => array:3 [ "titulo" => "Graphical abstract" "clase" => "graphical" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0025"></elsevierMultimedia></p></span>" ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S000173101630151X" "doi" => "10.1016/j.ad.2016.04.019" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173101630151X?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219016302207?idApp=UINPBA000044" "url" => "/15782190/0000010700000009/v1_201611010039/S1578219016302207/v1_201611010039/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review</span>" "titulo" => "Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part II: Photodynamic Therapy, Vismodegib, Cetuximab, Intralesional Methotrexate, and Radiotherapy" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "740" "paginaFinal" => "750" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "T. Gracia-Cazaña, N. Salazar, A. Zamarrón, M. Mascaraque, S.R. Lucena, Á. Juarranz" "autores" => array:6 [ 0 => array:4 [ "nombre" => "T." "apellidos" => "Gracia-Cazaña" "email" => array:2 [ 0 => "tamgracaz@gmail.com" 1 => "tamara_gracia@hotmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "N." "apellidos" => "Salazar" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 2 => array:3 [ "nombre" => "A." "apellidos" => "Zamarrón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "M." "apellidos" => "Mascaraque" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 4 => array:3 [ "nombre" => "S.R." "apellidos" => "Lucena" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 5 => array:3 [ "nombre" => "Á." "apellidos" => "Juarranz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Unidad de Dermatología, Hospital de Barbastro, Barbastro, Huesca, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Departamento de Biología, Facultad de Ciencias, Universidad Autónoma de Madrid, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Resistencias al tratamiento no quirúrgico en cáncer cutáneo no melanoma. Parte II: terapia fotodinámica, vismodegib, cetuximab, metotrexato intralesional y radioterapia" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1559 "Ancho" => 2462 "Tamanyo" => 297737 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Diagram showing the mechanism of action of vismodegib and different mutations in the Hedgehog (HH) pathway that cause tumor resistance. SMO indicates smoothened; PTCH, patched.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Skin cancer is the most common malignancy in the white population. The most common types include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), followed at a distance by melanoma. According to statistical analyses, the incidence of these 3 skin cancers has increased worldwide in the last 20 years, although mortality rates have remained stable. An incidence of 2.53 cases per 1000 population per year has been reported for BCC.<a class="elsevierStyleCrossRef" href="#bib0615"><span class="elsevierStyleSup">1</span></a> However, according to a recent study, the annual incidence of nonmelanoma skin cancer (NMSC) is underestimated, at 113 cases per 100<span class="elsevierStyleHsp" style=""></span>000 population for BCC and 38 cases per 100<span class="elsevierStyleHsp" style=""></span>000 population for SCC.<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Surgery is the most common treatment for NMSC, and in most cases it is curative. Nonetheless, 15.7% of NMSCs have positive margins<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">3</span></a> and complete excision is associated with a recurrence rate of 4.2%, although lower rates have been described for excision with wide margins, albeit with large surgical defects.<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">As mentioned in the first part of this review, a wide range of alternatives to surgery have emerged in recent years in the form of topical treatments and, even more recently, targeted therapies such as vismodegib and cetuximab, without forgetting of course other treatments that already existed, such as photodynamic therapy (PDT), radiotherapy, and even intralesional chemotherapy. One of the main reasons for treatment failure in cancer is resistance. The study of clinical, histologic, and biologic differences in responses to different treatments enhances our understanding of the mechanisms involved in resistance in NMSC and will help to achieve improved efficacy and efficiency by identifying patients who are more likely to respond favorably to a given treatment.</p><p id="par0020" class="elsevierStylePara elsevierViewall">In this article, we discuss the main mechanisms that have been investigated in treatment resistance in NMSC. The mechanisms described for PDT, vismodegib, and cetuximab are summarized in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Resistance to PDT</span><p id="par0025" class="elsevierStylePara elsevierViewall">PDT takes advantage of the photosensitizing properties of certain compounds that are activated by light and that, in the presence of molecular oxygen (O<span class="elsevierStyleInf">2</span>), generate reactive oxygen species (ROS) that induce cell death (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). The treatment has 3 basic components: a photosensitizing agent, light, and 0<span class="elsevierStyleInf">2</span>.<a class="elsevierStyleCrossRefs" href="#bib0635"><span class="elsevierStyleSup">5,6</span></a></p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">The antitumor properties of PDT are the result of direct cytotoxic effects on the tumor cells and indirect effects on the tumor stroma. Treatment also produces inflammation and elicits an immune response against the tumor, which is essential to achieve long-term control.<a class="elsevierStyleCrossRefs" href="#bib0635"><span class="elsevierStyleSup">5,7,8</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">The main photosensitizing agents approved for use in skin cancer in Europe are 5-aminolevulinic acid (ALA, Ameluz) and its methylated derivative MAL (Metvix). Both are precursors of the endogenous photosensitizer protoporphyrin IX (PpIX), which is a metabolite in the heme pathway. This pathway is subject to negative feedback control, and therefore exogenously administered ALA or MAL results in the accumulation of PpIX in tumor cells. In Spain, MAL is approved for the treatment of actinic keratosis (AK), Bowen disease, superficial BCCs, and nodular BCCs with a depth of less than 2<span class="elsevierStyleHsp" style=""></span>mm, while ALA is approved only for the treatment of AK.<a class="elsevierStyleCrossRefs" href="#bib0635"><span class="elsevierStyleSup">5,9</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">The advantages of PDT include high levels of complete response, with rates of 91% and 76% reported for BCC (at 3 months and 5 years, respectively) and of 86% to 93% and 68% to 71% for Bowen disease (at 3 and 24 months, respectively).<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">10</span></a> In a study of AK, a single PDT session with ALA (Levulan and Kerastick) produced respective cure rates of 76% and 72% at 1 and 2 months posttreatment. These rates increased to 86% with the administration of a second session.<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">11</span></a> In another study, PDT with MAL (Metvix) achieved a lesion response rate of between 69% and 91% at 3 months.<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">12</span></a> Low recurrence has been reported for PDT with MAL, with reports of a 15% clearance rate for BCC at 24 months<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">13</span></a> and a 5% and 25% rate for Bowen disease and AK, respectively, at 12 months.<a class="elsevierStyleCrossRefs" href="#bib0680"><span class="elsevierStyleSup">14,15</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Other advantages of PDT are that it can be combined with other treatments<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">16</span></a> and repeated as often as necessary, not to mention of course that it is associated with excellent cosmetic results and high satisfaction rates among patients.<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">17</span></a> It does, however, have some disadvantages, such as pain during illumination, the limited penetration capacity of both the photosensitizing agent and the light, and the risk of resistance, with occasional reports of refractory tumors.<a class="elsevierStyleCrossRefs" href="#bib0700"><span class="elsevierStyleSup">18,19</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Several clinical factors have been linked to resistance to PDT, but tumor thickness is the most widely studied factor, particularly in BCC. McKay et al.<a class="elsevierStyleCrossRef" href="#bib0710"><span class="elsevierStyleSup">20</span></a> reported that the likelihood of recurrence was greater in tumors thicker than 0.4<span class="elsevierStyleHsp" style=""></span>mm, and treatment guidelines do not recommend PDT for nodular BCCs with a thickness of over 2<span class="elsevierStyleHsp" style=""></span>mm.<a class="elsevierStyleCrossRef" href="#bib0715"><span class="elsevierStyleSup">21</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">Within the histological subtypes of BCC, pigmented tumors are the most difficult to treat, as the melanin absorbs the light, leaving the deepest part of the tumor without the light it needs to trigger the photodynamic reaction, possibly giving rise to resistance.<a class="elsevierStyleCrossRef" href="#bib0720"><span class="elsevierStyleSup">22</span></a> Morpheaform and infiltrative BCCs are also more resistant to the penetration of the photosensitizer due to the increased density of collagen and cords of cells in the connective tissue; PDT is therefore not indicated in these tumors.<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">15</span></a> Other factors that have been investigated include ulceration, an infiltrative growth pattern<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">23</span></a> and hyperkeratosis,<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">24</span></a> which can be a negative predictor of response.</p><p id="par0060" class="elsevierStylePara elsevierViewall">According to some authors, giant tumors (><span class="elsevierStyleHsp" style=""></span>4<span class="elsevierStyleHsp" style=""></span>cm in the case of BCCs) can predict poor response to PDT.<a class="elsevierStyleCrossRefs" href="#bib0735"><span class="elsevierStyleSup">25,26</span></a> However, other authors have found tumor diameter to have no effect on response.<a class="elsevierStyleCrossRefs" href="#bib0745"><span class="elsevierStyleSup">27–30</span></a> In a study of Bowen disease, Calzavara-Pinton et al.<a class="elsevierStyleCrossRef" href="#bib0765"><span class="elsevierStyleSup">31</span></a> found that tumor diameter was not a predictor of final response, but they did observe an association with recurrence.</p><p id="par0065" class="elsevierStylePara elsevierViewall">BCCs on the face or scalp are associated with lower rates of complete response than lesions on the trunk or neck (54% vs 88% at 24 months).<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">29</span></a> Complete response rates are also lower in the H-zone of the face, regardless of tumor size.<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">29</span></a> Nevertheless, in AK, studies comparing PDT and cryotherapy have found that lesions on the extremities appear to be more resistant to MAL-PDT than lesions on the face or scalp.<a class="elsevierStyleCrossRefs" href="#bib0770"><span class="elsevierStyleSup">32,33</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">Efficacy can also be affected by nonclinical factors. It is known, for example, that tumor cells do not always respond to the oxidative stress caused by PDT. These unresponsive cells are thought to be responsible for recurrent lesions that may become more aggressive. Resistance is generally thought to be due to intrinsic factors inherent to the tumor cells or extrinsic factors in the tumor environment, which has an important role in treatment response through the establishment of gradients in factors such as signaling, O<span class="elsevierStyleInf">2</span>, and metabolites.<a class="elsevierStyleCrossRefs" href="#bib0780"><span class="elsevierStyleSup">34,35</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">Intrinsic resistance may be due to a complex set of factors, including aspects related to the expression of genes involved in the genesis of NMSC and other aspects related to the photodynamic process itself.<a class="elsevierStyleCrossRef" href="#bib0790"><span class="elsevierStyleSup">36</span></a> UV light–induced DNA mutations in tumor suppressor genes, such as <span class="elsevierStyleItalic">p53</span>, are common and have been described as early events in the carcinogenesis of 50% of BCCs and AKs and in 90% of SCCs.<a class="elsevierStyleCrossRefs" href="#bib0795"><span class="elsevierStyleSup">37,38</span></a> There have also been reports of cyclin D1 overexpression in almost 50% of cases of AK, alterations of the Wnt/β-catenin signaling pathway (involved in SCC), and mutations in the <span class="elsevierStyleItalic">PTCH1</span> gene (which codes for the Hedgehog [HH] protein receptor in BCC), possibly affecting response to PDT.<a class="elsevierStyleCrossRefs" href="#bib0800"><span class="elsevierStyleSup">38,39</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">Another mechanism of interest is intracellular drug concentration, which is regulated by transporters such as P-glycoprotein (Pgp) responsible for transporting the drug out of the cell. While some studies have reported Pgp overexpression in epithelial cell lines such as MA104 (a clonal population derived from the kidney of an African green monkey, <span class="elsevierStyleItalic">Cercopithecus aethiops</span>) and MCDK 60, and in K562 chronic myeloid leukemia cells made resistant to PDT by multiple treatment cycles, others have not.<a class="elsevierStyleCrossRefs" href="#bib0810"><span class="elsevierStyleSup">40–44</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">The oxidative stress caused by PDT activates signaling cascades involved in survival, proliferation, and inhibition of apoptosis mediated by protein kinase B (PKB/Akt), nuclear factor k (NF-kB), mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3<span class="elsevierStyleHsp" style=""></span>K), and cyclooxygenase-2 (COX-2), as well as genes involved in the antioxidant response pathway, such as the nuclear factor (erythroid-derived 2)-like 2 (<span class="elsevierStyleItalic">Nrf2</span>) gene. COX-2, which participates in prostaglandin (PGE) synthesis and inflammatory responses<a class="elsevierStyleCrossRefs" href="#bib0835"><span class="elsevierStyleSup">45,46</span></a> is overexpressed in NMSC and is considered an early marker of actinic damage. MAPK pathways can be activated by PDT and may have a relevant role in resistance to this treatment.<a class="elsevierStyleCrossRef" href="#bib0790"><span class="elsevierStyleSup">36</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">PDT also results in the activation of the Nrf2 pathway, which is the main regulator of cellular responses to oxidative stress. Nrf2 activates the transcription of genes with an AU-rich element (ARE) in their promoter region, such as glutathione S-transferase (<span class="elsevierStyleItalic">GSH</span>), NAD(P)H quinone dehydrogenase 1 (<span class="elsevierStyleItalic">NQO1</span>), hem oxygenase 1, and superoxide dismutase, among others. The corresponding enzymes would have a key role in neutralizing ROS and promoting detoxification, possibly favoring resistance to PDT.<a class="elsevierStyleCrossRef" href="#bib0845"><span class="elsevierStyleSup">47</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">Some studies have also reported an association between PDT resistance and autophagy, via the reduction of immune effector mechanisms,<a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">48</span></a> and cytoskeleton and cell adhesion proteins.<a class="elsevierStyleCrossRef" href="#bib0855"><span class="elsevierStyleSup">49</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">Furthermore, it has been well established that nitric oxide mediates cell survival, growth, migration, and invasion in a wide variety of tumors. PDT induces nitric oxide production in the tumor and tumor microenvironment. Low levels of nitric oxide exert a cytoprotective effect by activating NF-kB/Snail YY1, enhancing survival/antiapoptosis and inhibiting the antisurvival/proapoptotic and metastasis suppressor Raf kinase inhibitory protein (RKIP).<a class="elsevierStyleCrossRefs" href="#bib0860"><span class="elsevierStyleSup">50,51</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Few publications have analyzed the mechanisms that determine poor tumor response to PDT and even fewer have analyzed these in NMSC, although it is an area of growing research interest. Numerous studies have shown resistance to PDT in preclinical studies using cell and animal models,<a class="elsevierStyleCrossRefs" href="#bib0810"><span class="elsevierStyleSup">40–43,52–54</span></a> and also in patients.<a class="elsevierStyleCrossRefs" href="#bib0705"><span class="elsevierStyleSup">19,55,56</span></a> Our group observed resistance to MAL-PDT in murine keratinocyte cultures (Pam-212) with activation of the PI3<span class="elsevierStyleHsp" style=""></span>K/Akt pathway.<a class="elsevierStyleCrossRef" href="#bib0895"><span class="elsevierStyleSup">57</span></a> Activation of the PI3<span class="elsevierStyleHsp" style=""></span>K/Akt<a class="elsevierStyleCrossRef" href="#bib0900"><span class="elsevierStyleSup">58</span></a> and MAPK/ERK pathways has been identified in PDT-resistant cells isolated from the human SCC cell line SCC-13 and points to a possible relationship with the more aggressive nature of invasive SCCs in patients who have undergone PDT.<a class="elsevierStyleCrossRef" href="#bib0705"><span class="elsevierStyleSup">19</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">Finally, PDT with low doses of MAL has been found to stimulate ROS-mediated growth of cultured cells,<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">59</span></a> adding some strength to the hypothesis that low doses of ROS could stimulate the growth of tumor cells in areas that receive an insufficient PDT dose.</p><p id="par0115" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Key point:</span></span> Diverse resistance mechanisms have been described for PDT. These include clinical factors, such as tumor thickness, size, location; histologic subtype; and molecular factors such as Pgp overexpression, MAPK pathway alterations, resistance secondary to Nrf2 and activation of the transcription of genes with an ARE in their promoter regions; autophagy and reduced immune effector mechanisms; and a PDT-induced cytoprotective effect of nitric oxide that activates NF-kB/Snail YY1 and inhibits RKIP, favoring tumor survival.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Resistance to Methotrexate</span><p id="par0120" class="elsevierStylePara elsevierViewall">Intralesional methotrexate has been shown to be an effective adjuvant to surgery in the treatment of keratoacanthoma<a class="elsevierStyleCrossRefs" href="#bib0910"><span class="elsevierStyleSup">60,61</span></a> and SCC.<a class="elsevierStyleCrossRef" href="#bib0920"><span class="elsevierStyleSup">62</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">Methotrexate is a folic acid analog that binds to dihydrofolate reductase, inhibiting DNA synthesis and ultimately causing cell death. Keratoacanthoma is a fast-growing tumor that frequently reaches a considerable size and can leave considerable functional and cosmetic defects when removed surgically. Annest et al.<a class="elsevierStyleCrossRef" href="#bib0925"><span class="elsevierStyleSup">63</span></a> reported a cure rate of 92% in a study of 38 patients with keratoacanthomas treated with a mean of 2.1 injections of methotrexate over an average of 18 days.</p><p id="par0130" class="elsevierStylePara elsevierViewall">Growth rate can determine sensitivity or resistance to methotrexate in keratoacanthoma. Sensitivity, for instance, is high in the early stages of growth but is of little consequence at later stages, when growth is slower.<a class="elsevierStyleCrossRef" href="#bib0930"><span class="elsevierStyleSup">64</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">Although there are no standardized protocols for the use of methotrexate in the treatment of keratoacanthoma, drug concentration (generally 12.5-25<span class="elsevierStyleHsp" style=""></span>mg/mL) and/or frequency of injections (1-4 weekly) appear to be related to tumor response.<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">65</span></a></p><p id="par0140" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Key point:</span></span> The growth rate of keratoacanthomas appears to influence response to treatment, with higher resistance rates seen in slow-growing tumors.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Resistance to Vismodegib</span><p id="par0145" class="elsevierStylePara elsevierViewall">Vismodegib (GDC-0449) is an oral molecule that selectively inhibits the HH signaling pathway. It is the first drug available for the treatment of locally advanced and metastatic BCC.<a class="elsevierStyleCrossRefs" href="#bib0940"><span class="elsevierStyleSup">66,67</span></a></p><p id="par0150" class="elsevierStylePara elsevierViewall">Three HH signaling molecules have been described in vertebrates: Indian HH (expressed in the intestine and chondrocytes), Desert HH (expressed in Sertoli cells), and the better-known Sonic HH, which has been linked to many processes. The HH signaling pathway is composed of 3 basic elements: HH ligands, the inhibitory receptor Patched (PTCH), and the signaling receptor Smoothened (SMO).<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">68</span></a></p><p id="par0155" class="elsevierStylePara elsevierViewall">The PTCH protein is the Sonic HH receptor and negatively regulates this pathway. The SMO protein, by contrast, positively regulates the pathway and is permanently activated in the absence of PTCH. SMO also activates Gli transcription factors, which penetrate the nucleus, activating the transcription of genes involved in cell growth, which, in turn control PTCH and Gli via a negative feedback mechanism. The result is activation of the pathway, with proliferation, apoptosis, and epidermal differentiation (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). Proteolyzed Gli factors act as transcription inhibitors and their proteolysis depends on binding to microtubules and to suppressor of fused (Sufu) proteins that, when bound to Gli, prevent the activation of the target genes in the HH pathway.<a class="elsevierStyleCrossRefs" href="#bib0955"><span class="elsevierStyleSup">69–71</span></a></p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0160" class="elsevierStylePara elsevierViewall">UV radiation–induced mutations can be found in the HH pathway in sporadic BCC; 80% are caused by inactivation of <span class="elsevierStyleItalic">PTCH1</span>, 10% by <span class="elsevierStyleItalic">SMO</span> gain-of-function mutations, and just 1% by <span class="elsevierStyleItalic">Sufu</span> mutations.<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">68</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">Vismodegib binds to and specifically inactivates SMO, preventing the activation of Gli, and thereby halting cell proliferation and tumor growth. In a phase I clinical trial, Von Hoff et al.<a class="elsevierStyleCrossRef" href="#bib0970"><span class="elsevierStyleSup">72</span></a> observed respective response rates of 60% and 50% for locally advanced and metastatic BCCs treated with vismodegib. Phase II studies have shown that a daily dose of vismodegib 150<span class="elsevierStyleHsp" style=""></span>mg produces a partial response rate of 30.3% in metastatic BCC and 22.2% in locally advanced BCC and a complete response rate of 20.6% in locally advanced BCC.<a class="elsevierStyleCrossRef" href="#bib0975"><span class="elsevierStyleSup">73</span></a></p><p id="par0170" class="elsevierStylePara elsevierViewall">Resistance to treatment, however, has also been reported since the approval of vismodegib. The first case corresponded to a patient with medulloblastoma due to a <span class="elsevierStyleItalic">PTCH1</span> mutation (PTCH1-W844<span class="elsevierStyleHsp" style=""></span>C) and mutations in other genes involved in the HH pathway, leading to rapid disease progression. Since then, there have been reports of isolated, mostly heterozygous, <span class="elsevierStyleItalic">SMO</span> mutations.<a class="elsevierStyleCrossRefs" href="#bib0980"><span class="elsevierStyleSup">74–76</span></a></p><p id="par0175" class="elsevierStylePara elsevierViewall">Brinkhuizen et al<a class="elsevierStyleCrossRef" href="#bib0995"><span class="elsevierStyleSup">77</span></a> investigated acquired resistance to vismodegib, i.e., resistance related to mutations present in the resistant tumor but not in the primary, untreated, tumor. They found 2 <span class="elsevierStyleItalic">SMO</span> mutations: c.842G[T (p.Trp281Leu) in exon 4 and c.961G[A(p.Val321Met) in exon 5.</p><p id="par0180" class="elsevierStylePara elsevierViewall">Pricl et al.<a class="elsevierStyleCrossRef" href="#bib1000"><span class="elsevierStyleSup">78</span></a> studied primary and acquired resistance to vismodegib in 2 patients. The first patient had metastatic BCC in which disease progression (primary resistance) was confirmed by computed tomography 2 months after treatment with vismodegib 150<span class="elsevierStyleHsp" style=""></span>mg/d. The second patient had an unresectable large (12<span class="elsevierStyleHsp" style=""></span>cm) ulcerated locally advanced BCC in the suprascapular region, also treated with vismodegib 150<span class="elsevierStyleHsp" style=""></span>mg/d. Although the treatment resulted in a complete clinical response at 5 months, the tumor returned 6 months later (acquired resistance). The authors detected a new mutation, <span class="elsevierStyleItalic">SMO</span> G497<span class="elsevierStyleHsp" style=""></span>W, in the first case, and in the second case, they found a <span class="elsevierStyleItalic">SMO</span> D473Y mutation only in the biopsy sample of the pretreatment tumor. The first mutation gave rise to a conformational rearrangement of the protein that resulted in a partial obstruction of the drug entry site, while the second mutation induced a direct effect on binding site geometry, giving rise to compete disruption of hydrogen bond formation. The mutations may therefore reflect different mechanisms.</p><p id="par0185" class="elsevierStylePara elsevierViewall">In a recent whole-exome sequencing study of BCC, Sharpe et al.<a class="elsevierStyleCrossRef" href="#bib1005"><span class="elsevierStyleSup">79</span></a> observed intratumoral heterogeneity, without mutations in the pretreatment biopsies, providing evidence that the mutations were all acquired and led to hyperactivation of the HH pathway. These mutations affected 2 regions of the <span class="elsevierStyleItalic">SMO</span> gene: the drug binding pocket and a distal location, suggesting possible cross-resistance. Copy number variations were also observed for <span class="elsevierStyleItalic">Sufi</span> and <span class="elsevierStyleItalic">Gli2</span>, but to a lesser extent.</p><p id="par0190" class="elsevierStylePara elsevierViewall">Other mechanisms of resistance observed include mutations in the target HH gene cyclin D1 (<span class="elsevierStyleItalic">CCND1</span>)<a class="elsevierStyleCrossRefs" href="#bib0990"><span class="elsevierStyleSup">76,80</span></a> and compensatory upregulation of IGF-1R/PI3<span class="elsevierStyleHsp" style=""></span>K as a possible pathway involved in the development of resistance to SMO inhibitors. This mechanism has been observed in LDE-225-resistant tumors.<a class="elsevierStyleCrossRefs" href="#bib1010"><span class="elsevierStyleSup">80,81</span></a></p><p id="par0195" class="elsevierStylePara elsevierViewall">Current research efforts are focused on new therapeutic targets and the development of second-generation inhibitors that remain active in the presence of mutations. Among the strategies being contemplated is inhibition of the HH pathway through itraconazole or arsenic oxide, which are both HH signaling pathway antagonists with a different mechanism of action to vismodegib.<a class="elsevierStyleCrossRefs" href="#bib1020"><span class="elsevierStyleSup">82,83</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">An alternative approach might consist of blocking other pathways that interact with the HH signaling pathway in BCC and give rise to SMO-independent activation of Gli1, such as EGFR,<a class="elsevierStyleCrossRef" href="#bib1030"><span class="elsevierStyleSup">84</span></a> atypical protein kinase C ι/λ,<a class="elsevierStyleCrossRef" href="#bib1035"><span class="elsevierStyleSup">85</span></a> protein kinase A,<a class="elsevierStyleCrossRef" href="#bib1040"><span class="elsevierStyleSup">86</span></a> and the RAS/MAPK and PI3<span class="elsevierStyleHsp" style=""></span>K pathways.<a class="elsevierStyleCrossRefs" href="#bib0960"><span class="elsevierStyleSup">70,81,87</span></a></p><p id="par0205" class="elsevierStylePara elsevierViewall">Despite an initial favorable response, patients treated with SMO inhibitors develop resistance due to compensatory mechanisms generated over time. Furthermore, SMO inhibitors are not efficient in tumors where HH hyperactivation is due to mutations of components along the distal SMO pathway, or in the case of noncanonical activation, explaining why SMO-independent Gli transcription factors are activated. For all these reasons, intensive research efforts have been focused on HH inhibitors that act downstream of SMO,<a class="elsevierStyleCrossRef" href="#bib1050"><span class="elsevierStyleSup">88</span></a> such as GANT61, which blocks Gli function,<a class="elsevierStyleCrossRef" href="#bib1055"><span class="elsevierStyleSup">89</span></a> and on a new class of drugs targeting extra C-terminal (BET) bromodomain proteins and the bromodomain proteins BRD2-4 and BRDT, which recognize acetylated lysine residues such as histone N-terminal lysine residues, giving rise to a protein-histone association and subsequent chromatin remodeling. BRD4 regulates Gli transcription by acting on Gli1 and Gli2 promoters, evading all SMO resistance mechanisms described to date, including <span class="elsevierStyleItalic">SMO</span> and <span class="elsevierStyleItalic">Sufu</span> mutations and <span class="elsevierStyleItalic">Gli2</span> amplifications.<a class="elsevierStyleCrossRefs" href="#bib1060"><span class="elsevierStyleSup">90,91</span></a></p><p id="par0210" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Key point:</span></span> Resistance to vismodegib is due to somatic mutations in <span class="elsevierStyleItalic">PTCH</span> and in <span class="elsevierStyleItalic">SMO</span> in particular, to mutations located distally to this transmembrane receptor, and to SMO-independent Gli activation and compensatory upregulation of IGF-1R/PI3<span class="elsevierStyleHsp" style=""></span>K.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resistance to EGF Receptor Antibodies (Cetuximab)</span><p id="par0215" class="elsevierStylePara elsevierViewall">The relatively recent approval of cetuximab, a monoclonal antibody that inhibits EGF receptor (EGFR) activity, has opened up new horizons for the systemic treatment of patients with unresectable or metastatic SCC. EGFR belongs to the ErbB receptor family, which has 4 members: ErbB1 (EGFR), ErbB2 (neu), ErbB3, and ErbB4.<a class="elsevierStyleCrossRef" href="#bib1070"><span class="elsevierStyleSup">92</span></a></p><p id="par0220" class="elsevierStylePara elsevierViewall">Binding of a ligand to the extracellular domain of the receptor activates several intracellular signaling pathways, including the PI3<span class="elsevierStyleHsp" style=""></span>K/Akt pathway, the signal transducer and activator of transcription (STAT) pathway, and the RAS-MAPK pathway, which are all involved in cell growth, proliferation, and/or survival (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>).<a class="elsevierStyleCrossRefs" href="#bib1070"><span class="elsevierStyleSup">92–94</span></a></p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0225" class="elsevierStylePara elsevierViewall">Recognition of the important role played by EGFR in human tumor cell proliferation, survival, and progression has led to the development of therapeutic targets, representing an important advance in oncology.<a class="elsevierStyleCrossRefs" href="#bib1085"><span class="elsevierStyleSup">95–99</span></a></p><p id="par0230" class="elsevierStylePara elsevierViewall">Expression of EGFR has been correlated with worse prognosis in SCC.<a class="elsevierStyleCrossRef" href="#bib1110"><span class="elsevierStyleSup">100</span></a> Blockage of EGFR with cetuximab has proven to be useful in SCC of the head and neck and, also, although there are fewer studies available, in locally advanced, unresectable, and metastatic cutaneous SCC. In one phase II clinical trial of 36 patients, cetuximab produced 8 partial responses, 2 complete responses, and a disease control rate of 69% at 6 weeks, with a median progression-free survival of 4.1 months. EGFR overexpression was an inclusion criterion in the trial, which showed an association between treatment efficacy and EGFR tumor expression levels. The authors also studied other mutations and concluded that a lack of <span class="elsevierStyleItalic">RAS</span> mutations increased tumor sensitivity to cetuximab.<a class="elsevierStyleCrossRef" href="#bib1115"><span class="elsevierStyleSup">101</span></a></p><p id="par0235" class="elsevierStylePara elsevierViewall">Molecular mechanisms possibly involved in treatment resistance in colorectal cancer and SCC of the head and neck include K-RAS mutations and constitutive activation of EGFR and its distal pathway.<a class="elsevierStyleCrossRefs" href="#bib1120"><span class="elsevierStyleSup">102–105</span></a></p><p id="par0240" class="elsevierStylePara elsevierViewall">Li et al.<a class="elsevierStyleCrossRef" href="#bib1140"><span class="elsevierStyleSup">106</span></a> described an association between acquired resistance to cetuximab and Src activity and EGFR-dependent nuclear translocation of Src. Other resistance mechanisms reported in the literature are PTEN instability, Akt hyperactivation,<a class="elsevierStyleCrossRef" href="#bib1145"><span class="elsevierStyleSup">107</span></a> increased expression of EGFR ligands,<a class="elsevierStyleCrossRefs" href="#bib1140"><span class="elsevierStyleSup">106,108</span></a> and positive regulation of EGFR, HER2, and HER3.<a class="elsevierStyleCrossRefs" href="#bib1155"><span class="elsevierStyleSup">109–112</span></a></p><p id="par0245" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Key point:</span></span> Mechanisms described for resistance to cetuximab include certain K-RAS mutations, constitutive EGFR activation, overexpression of nonmutated RAS, EGFR-dependent nuclear translocation of Src, PTEN instability, Akt hyperactivation, increased expression of EGFR ligands, and positive regulation of EGFR, HER2, and HER3.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Resistance to Radiotherapy</span><p id="par0250" class="elsevierStylePara elsevierViewall">Radiotherapy uses ionizing radiation to shrink or kill tumors. The radiation can damage cells either directly or indirectly through the production of ROS; DNA is the main target. There are 2 main types of ionizing radiation: photon radiation (x-rays and gamma rays), which is the most widely used, and particle radiation (electrons and protons, among others). In the first case, the effect are exerted through the production of free radicals, while in the second case, direct DNA damage is more important. Exposure to radiation can induce cell-cycle arrest, damage repair, or apoptosis, and in some cases it can promote cell division and generate resistance.<a class="elsevierStyleCrossRefs" href="#bib1175"><span class="elsevierStyleSup">113,114</span></a></p><p id="par0255" class="elsevierStylePara elsevierViewall">Radiotherapy is an effective first-line treatment for BCC and SCC, and it is associated with a 5-year cure rate of around 90%. It is also effective in skin cancers that have been surgically treated. It has been used for decades to treat NMSCs that have failed to respond to or were not suitable for other treatments. The adverse effects of ionizing radiation, however, are well-known and therefore the amount of radiation that can be applied is limited and recurrences may appear.<a class="elsevierStyleCrossRefs" href="#bib1185"><span class="elsevierStyleSup">115,116</span></a></p><p id="par0260" class="elsevierStylePara elsevierViewall">Most studies of radiotherapy in BCC have reported 5-year cure rates of over 90%, with very few complications. Radiotherapy can also be used in recurrent tumors, tumors with perineural invasion, and tumors with positive margins after SCC. It is also beneficial in certain anatomic locations, such as the lower eyelid, the lip, the tip of the nose, and the ear, where it is associated with an efficacy of between 70% and 95%. Recurrence rates are around 3% to 11%, although certain histologic differentiation grades and tumor sites are associated with higher rates.<a class="elsevierStyleCrossRefs" href="#bib1190"><span class="elsevierStyleSup">116–120</span></a></p><p id="par0265" class="elsevierStylePara elsevierViewall">Inhibition of EGFR and STAT3, which both have an important role in the transmission of growth signals initiated by EGFR, has been found to improve the effects of conventional treatments, such as radiotherapy in SCC. Accordingly, the constitutive activation of these factors can also give rise to less radiosensitive, i.e., more resistant, tumors.<a class="elsevierStyleCrossRef" href="#bib1215"><span class="elsevierStyleSup">121</span></a></p><p id="par0270" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic"><span class="elsevierStyleBold">Key point:</span></span> Activation of EGFR and STAT3 affect the radiosensitivity of SCC cells.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Resistance to Chemotherapy</span><p id="par0275" class="elsevierStylePara elsevierViewall">Various chemotherapy agents have been used in the treatment of SCC and advanced or unresectable BCC. In the first case, cisplatin has been used either alone or combined with other agents, and it has produced variable results. It has been mostly combined with bleomycin, doxorubicin, and 5-fluorouracil, and has also been used in combination with fluorouracil-based chemoradiation. However, its efficacy has not been demonstrated in randomized clinical trials and most of the data available are based on findings from small series. The most effective options for BCC appear to be cisplatin, used alone or in combination, and a regimen such as vincristine, bleomycin, and prednisolone. Nevertheless, with very few exceptions, long-term response rates have not been demonstrated for traditional chemotherapy, and it is therefore mainly used as a palliative treatment.<a class="elsevierStyleCrossRef" href="#bib1220"><span class="elsevierStyleSup">122</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Conclusions</span><p id="par0280" class="elsevierStylePara elsevierViewall">A wide variety of mechanisms have been described for resistance of NMSC to nonsurgical treatments. They include mechanisms related to intracellular drug transport (e.g., Ppg in PDT), mutations in target genes such as <span class="elsevierStyleItalic">SMO</span> with vismodegib, alterations to molecular pathways such as MAPK in PDT and EGFR inhibitors and even intrinsic cell characteristics such as adhesion molecules, cytoskeleton components, size, and tumor progression. Analysis of primary and acquired resistance mechanisms will help to extend knowledge of the biology of different types of tumor and open new avenues for the investigation of new targets and alternative pathways to treat recurrences and overcome lack of response.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Conflicts of Interest</span><p id="par0285" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:14 [ 0 => array:3 [ "identificador" => "xres750965" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec753737" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres750964" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec753738" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Resistance to PDT" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Resistance to Methotrexate" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Resistance to Vismodegib" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "Resistance to EGF Receptor Antibodies (Cetuximab)" ] 9 => array:2 [ "identificador" => "sec0030" "titulo" => "Resistance to Radiotherapy" ] 10 => array:2 [ "identificador" => "sec0035" "titulo" => "Resistance to Chemotherapy" ] 11 => array:2 [ "identificador" => "sec0040" "titulo" => "Conclusions" ] 12 => array:2 [ "identificador" => "sec0045" "titulo" => "Conflicts of Interest" ] 13 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-01-16" "fechaAceptado" => "2016-04-30" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec753737" "palabras" => array:7 [ 0 => "Skin cancer" 1 => "Cetuximab" 2 => "Vismodegib" 3 => "Photodynamic therapy" 4 => "Radiotherapy" 5 => "Methotrexate" 6 => "Drug resistance" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec753738" "palabras" => array:7 [ 0 => "Cáncer cutáneo" 1 => "Cetuximab" 2 => "Vismodegib" 3 => "Terapia fotodinámica" 4 => "Radioterapia" 5 => "Metotrexato" 6 => "Resistencia a fármacos" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A wide range of treatments is now available for nonmelanoma skin cancer, including 5-fluorouracil, ingenol mebutate, imiquimod, diclofenac, photodynamic therapy, methotrexate, cetuximab, vismodegib, and radiotherapy. All are associated with high clinical and histologic response rates. However, some tumors do not respond due to resistance, which may be primary or acquired. Study of the resistance processes is a broad area of research that aims to increase our understanding of the nature of each tumor and the biologic features that make it resistant, as well as to facilitate the design of new therapies directed against these tumors. In this second article, having covered the topical treatments of nonmelanoma skin cancer, we review resistance to other nonsurgical treatments, such as monoclonal antibodies against basal and squamous cell carcinomas, intralesional chemotherapy, photodynamic therapy, and radiotherapy.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">En la actualidad existe una amplia variedad de tratamientos para el cáncer cutáneo no melanoma, como son 5-fluoracilo, mebutato de ingenol, imiquimod, diclofenaco, terapia fotodinámica, metotrexato, cetuximab, vismodegib, radioterapia, todos ellos con altas tasas de respuesta clínica e histológica. Sin embargo, algunos tumores no responden al tratamiento, debido a la aparición de resistencias, tanto primarias como adquiridas. El estudio de los procesos de resistencia es un campo extenso de investigación que conlleva a ampliar los conocimientos de la naturaleza de cada tumor, las características biológicas que lo hacen resistente y el diseño de nuevas terapias dirigidas contra los mismos. En este segundo trabajo se revisan las resistencias descritas a otros tratamientos no quirúrgicos frente al cáncer cutáneo no melanoma, diferentes a los tratamientos tópicos, como son diferentes anticuerpos monoclonales frente a CBC y CEC, la quimioterapia intralesional, la terapia fotodinámica y la radioterapia.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Gracia-Cazaña T. Resistencias al tratamiento no quirúrgico en cáncer cutáneo no melanoma. Parte II: terapia fotodinámica, vismodegib, cetuximab, metotrexato intralesional y radioterapia. Actas Dermosifiliogr. 2016;107:740–750.</p>" ] ] "multimedia" => array:4 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 947 "Ancho" => 1630 "Tamanyo" => 147422 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Mechanism of action of photodynamic therapy. The absorption of light by a photosensitizer (PS) promotes an electron to a higher-energy orbit (excited single PS state), and the spin angular momentum of this electron is then reversed, causing an excited triplet PS state. The longer lifetime of the triplet state favors the generation of free radicals and/or singlet oxygen, which damage key cell structures and ultimately cause cell death. ROS indicates reactive oxygen species.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1559 "Ancho" => 2462 "Tamanyo" => 297737 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Diagram showing the mechanism of action of vismodegib and different mutations in the Hedgehog (HH) pathway that cause tumor resistance. SMO indicates smoothened; PTCH, patched.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1882 "Ancho" => 2476 "Tamanyo" => 329906 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Mechanism of action of cetuximab, which blocks EGFR, preventing the activation of several intracellular signaling pathways, including PI3<span class="elsevierStyleHsp" style=""></span>K/Akt, STAT, and RAS-MAPK. The graph shows the different mutations described to date in resistance to cetuximab in squamous cell carcinoma. EGFR indicates epidermal growth factor receptor; P, phosphorylation; P-Src, phosphorylated Src; STAT, signal transducer and activator of transcription.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: AK, actinic keratosis; BCC, basal cell carcinoma; EGFR, epidermal growth factor receptor; PDT, photodynamic therapy; ROS, reactive oxygen species.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Efficacy \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Resistance-Related Variables \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Photodynamic therapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Complete response in BCC: 91% at 3 mo and 76% at 5 y.<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">10</span></a> Recurrence at 24 mo: 15%<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">13</span></a><br>Complete response in Bowen disease: 86%-93% at 3 mo and 68%-71% at 24 mo.<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">10</span></a> Recurrence at 12 mo: 5%<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">14</span></a><br>Complete response in AK: 69%-91% at 3 mo.<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">12</span></a> Recurrence at 12 mo: 25%<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">15</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Thickness tumor (><span class="elsevierStyleHsp" style=""></span>2<span class="elsevierStyleHsp" style=""></span>mm)<a class="elsevierStyleCrossRef" href="#bib0710"><span class="elsevierStyleSup">20</span></a><br>Histologic subtypes (pigmented, morpheaform, and infiltrative BCC, infiltrative growth pattern)<a class="elsevierStyleCrossRefs" href="#bib0685"><span class="elsevierStyleSup">15,22,23</span></a><br>Ulceration<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">23</span></a><br>Hyperkeratosis<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">24</span></a><br>Certain locations in BCC (face and scalp)<a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">29</span></a><br>Mutations in <span class="elsevierStyleItalic">p53</span><a class="elsevierStyleCrossRefs" href="#bib0795"><span class="elsevierStyleSup">37,38</span></a>; overexpression of cyclin D1<a class="elsevierStyleCrossRefs" href="#bib0800"><span class="elsevierStyleSup">38,39</span></a>; alterations to Wnt/B-catenin pathway<a class="elsevierStyleCrossRefs" href="#bib0800"><span class="elsevierStyleSup">38,39</span></a>; mutations in <span class="elsevierStyleItalic">PTCH1</span><a class="elsevierStyleCrossRefs" href="#bib0800"><span class="elsevierStyleSup">38,39</span></a>; altered expression of P-glycloprotein<a class="elsevierStyleCrossRefs" href="#bib0810"><span class="elsevierStyleSup">40–44</span></a>Activation of MAPK and Nrf2 pathways<a class="elsevierStyleCrossRefs" href="#bib0835"><span class="elsevierStyleSup">45,46</span></a><br>Autophagy and reduction of immune effector mechanisms<a class="elsevierStyleCrossRef" href="#bib0850"><span class="elsevierStyleSup">48</span></a><br>Changes to cytoskeleton and cell adhesion proteins<a class="elsevierStyleCrossRef" href="#bib0855"><span class="elsevierStyleSup">49</span></a><br>PDT-induced cytoprotective effect of nitric oxide<a class="elsevierStyleCrossRefs" href="#bib0860"><span class="elsevierStyleSup">50,51</span></a><br>Low dose of ROS with stimulation of tumor cells<a class="elsevierStyleCrossRef" href="#bib0905"><span class="elsevierStyleSup">59</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Vismodegib \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Partial response in metastatic BCC: 30.3% Mean duration of response: 7.6 mo<a class="elsevierStyleCrossRef" href="#bib0975"><span class="elsevierStyleSup">73</span></a><br>Complete and partial response in locally advanced BCC: 20.6% and 22.2% respectively. Mean duration of response: 7.6 mo<a class="elsevierStyleCrossRef" href="#bib0975"><span class="elsevierStyleSup">73</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Mutations in <span class="elsevierStyleItalic">PTCH1</span><a class="elsevierStyleCrossRef" href="#bib0985"><span class="elsevierStyleSup"><span class="elsevierStyleItalic">75</span></span></a><br>Mainly mutations in <span class="elsevierStyleItalic">SMO</span><br>Copy-number variations in <span class="elsevierStyleItalic">Sufu</span> and <span class="elsevierStyleItalic">Gli</span><a class="elsevierStyleCrossRef" href="#bib1005"><span class="elsevierStyleSup">79</span></a><br>Mutations in cyclin D1 (<span class="elsevierStyleItalic">CCND1</span>)<a class="elsevierStyleCrossRefs" href="#bib0990"><span class="elsevierStyleSup">76,80</span></a><br>Compensatory upregulation of IGF-1R/PI3K<a class="elsevierStyleCrossRefs" href="#bib1010"><span class="elsevierStyleSup">80,81</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Cetuximab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Complete response: 5%<br>Partial response: 22.2%<br>Disease control: 69%; median progression-free survival: 4.1 mo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Lack of mutations in RAS<a class="elsevierStyleCrossRef" href="#bib1115"><span class="elsevierStyleSup">101</span></a><br>Src activity and EGFR-dependent nuclear translocation of Src<a class="elsevierStyleCrossRef" href="#bib1140"><span class="elsevierStyleSup">106</span></a><br>PTEN instability, Akt hyperactivation<a class="elsevierStyleCrossRef" href="#bib1145"><span class="elsevierStyleSup">107</span></a><br>Increased expression of EGFR ligands<a class="elsevierStyleCrossRefs" href="#bib1140"><span class="elsevierStyleSup">106,108</span></a><br>Upregulation of EGFR, HER2, and HER 33<a class="elsevierStyleCrossRefs" href="#bib1155"><span class="elsevierStyleSup">109–112</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1242577.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Summary of Efficacy Rates and Resistance Mechanisms Described for Photodynamic Therapy, Vismodegib, and Cetuximab.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:122 [ 0 => array:3 [ "identificador" => "bib0615" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Population-based incidence of basal cell carcinoma in a Spanish Mediterranean area" "autores" => array:1 [ 0 => array:3 [ …3] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2009.09468.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2009" "volumen" => "161" "paginaInicial" => "1341" "paginaFinal" => "1346" "link" => array:1 [ …1] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0620" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Skin cancer incidence and mortality in Spain: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2015.12.008" "Revista" => array:7 [ "tituloSerie" => "Actas Dermosifiliogr." "fecha" => "2016" "volumen" => "107" "paginaInicial" => "318" "paginaFinal" => "328" "link" => array:1 [ …1] "itemHostRev" => array:3 [ …3] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0625" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A prospective study of the accuracy of the surgeon's diagnosis and significance of positive margins in nonmelanoma skin cancers" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Plast Reconstr Surg" "fecha" => "2001" "volumen" => "107" "paginaInicial" => "942" "paginaFinal" => "947" "link" => array:1 [ …1] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0630" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recurrence after treatment of nonmelanoma skin cancer: A prospective cohort study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archdermatol.2011.109" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2011" "volumen" => "147" "paginaInicial" => "540" "paginaFinal" => "546" "link" => array:1 [ …1] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0635" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy of cancer: An update" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3322/caac.20114" "Revista" => array:6 [ "tituloSerie" => "CA Cancer J Clin" "fecha" => "2011" "volumen" => "61" "paginaInicial" => "250" "paginaFinal" => "281" "link" => array:1 [ …1] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0640" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy (PDT): PDT mechanisms" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5946/ce.2013.46.1.24" "Revista" => array:6 [ "tituloSerie" => "Clin Endosc" "fecha" => "2013" "volumen" => "46" "paginaInicial" => "24" "paginaFinal" => "29" "link" => array:1 [ …1] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0645" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Direct and indirect photodynamic therapy effects on the cellular and molecular components of the tumor microenvironment" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bbcan.2012.10.001" "Revista" => array:6 [ "tituloSerie" => "Biochim Biophys Acta" "fecha" => "2013" "volumen" => "1835" "paginaInicial" => "36" "paginaFinal" => "45" "link" => array:1 [ …1] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0650" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Immunogenic cell death: Can it be exploited in photodynamic therapy for cancer?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2013/482160" "Revista" => array:5 [ "tituloSerie" => "Biomed Res Int" "fecha" => "2013" "volumen" => "2013" "paginaInicial" => "482160" "link" => array:1 [ …1] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0655" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy in dermatology: Past, present, and future" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1117/1.JBO.18.6.061208" "Revista" => array:5 [ "tituloSerie" => "J Biomed Opt" "fecha" => "2013" "volumen" => "18" "paginaInicial" => "061208" "link" => array:1 [ …1] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0660" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European guidelines for topical photodynamic therapy part 1: Treatment delivery and current indications-actinic keratoses, Bowen's disease, basal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.12031" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2013" "volumen" => "27" "paginaInicial" => "536" "paginaFinal" => "544" "link" => array:1 [ …1] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0665" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: Phase IV multicentre clinical trial with 12-month follow up" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2006.07520.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2006" "volumen" => "155" "paginaInicial" => "1262" "paginaFinal" => "1269" "link" => array:1 [ …1] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0670" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Terapia fotodinámica: estudios con metilaminolevulinato en queratosis actínicas" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2010" "volumen" => "101" "paginaInicial" => "315" "paginaFinal" => "322" "link" => array:1 [ …1] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0675" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.143.9.1131" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2007" "volumen" => "143" "paginaInicial" => "1131" "paginaFinal" => "1136" "link" => array:1 [ …1] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0680" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy in the treatment of extensive Bowen's disease" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/09546634.2011.590789" "Revista" => array:6 [ "tituloSerie" => "J Dermatolog Treat" "fecha" => "2012" "volumen" => "23" "paginaInicial" => "428" "paginaFinal" => "430" "link" => array:1 [ …1] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0685" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methylaminolaevulinate for the treatment of actinic keratosis" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.12158" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2013" "volumen" => "168" "paginaInicial" => "825" "paginaFinal" => "836" "link" => array:1 [ …1] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0690" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Combined treatments with photodynamic therapy for non-melanoma skin cancer" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/ijms161025912" "Revista" => array:6 [ "tituloSerie" => "Int J Mol Sci" "fecha" => "2015" "volumen" => "16" "paginaInicial" => "25912" "paginaFinal" => "25933" "link" => array:1 [ …1] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0695" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "[Epub ahead of print]" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Patient satisfaction in the photodynamic therapy clinic" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/phpp.12218" "Revista" => array:2 [ "tituloSerie" => "Photodermatol Photoimmunol Photomed" "fecha" => "2015" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0700" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: Results of a multicenter randomized prospective trial" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.140.1.17" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2004" "volumen" => "140" "paginaInicial" => "17" "paginaFinal" => "23" "link" => array:1 [ …1] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0705" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cellular intrinsic factors involved in the resistance of squamous cell carcinoma to photodynamic therapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/jid.2014.178" "Revista" => array:6 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "2014" "volumen" => "134" "paginaInicial" => "2428" "paginaFinal" => "2437" "link" => array:1 [ …1] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0710" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: A proposal for a thickness-based definition of sBCC" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.12402" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2013" "volumen" => "169" "paginaInicial" => "549" "paginaFinal" => "554" "link" => array:1 [ …1] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0715" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2006.06.006" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2007" "volumen" => "56" "paginaInicial" => "125" "paginaFinal" => "143" "link" => array:1 [ …1] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0720" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Experience and BCC subtypes as determinants of MAL-PDT response: Preliminary results of a national Brazilian project" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pdpdt.2013.11.001" "Revista" => array:6 [ "tituloSerie" => "Photodiagnosis Photodyn Ther" "fecha" => "2014" "volumen" => "11" "paginaInicial" => "22" "paginaFinal" => "26" "link" => array:1 [ …1] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0725" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy for basal cell carcinoma: Clinical and pathological determinants of response" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2010.03877.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2011" "volumen" => "25" "paginaInicial" => "896" "paginaFinal" => "901" "link" => array:1 [ …1] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0730" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines for practical use of MAL-PDT in non-melanoma skin cancer" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2009.03430.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2010" "volumen" => "24" "paginaInicial" => "505" "paginaFinal" => "512" "link" => array:1 [ …1] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0735" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sequential treatment of giant basal cell carcinomas" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Plast Reconstr Aesthet Surg" "fecha" => "2009" "volumen" => "62" "paginaInicial" => "368" "paginaFinal" => "372" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0740" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy in dermatology" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "1998" "volumen" => "134" "paginaInicial" => "207" "paginaFinal" => "214" "link" => array:1 [ …1] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0745" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-4632.2008.04022.x" "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "2009" "volumen" => "48" "paginaInicial" => "1236" "paginaFinal" => "1245" "link" => array:1 [ …1] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0750" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20<span class="elsevierStyleHsp" style=""></span>mm), with a 12-month follow-up" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2008.02803.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2008" "volumen" => "22" "paginaInicial" => "1302" "paginaFinal" => "1311" "link" => array:1 [ …1] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0755" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy with topical methyl aminolaevulinate for ‘difficult-to-treat’ basal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2005.06484.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2005" "volumen" => "152" "paginaInicial" => "765" "paginaFinal" => "772" "link" => array:1 [ …1] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0760" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2001" "volumen" => "137" "paginaInicial" => "319" "paginaFinal" => "324" "link" => array:1 [ …1] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0765" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methylaminolaevulinate-based photodynamic therapy of Bowen's disease and squamous cell carcinoma" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08593.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "159" "paginaInicial" => "137" "paginaFinal" => "144" "link" => array:1 [ …1] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0770" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intraindividual, right–left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2006.07470.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2006" "volumen" => "155" "paginaInicial" => "1029" "paginaFinal" => "1036" "link" => array:1 [ …1] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0775" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multicentre intraindividual randomized trial of topical methyl aminolaevulinate–photodynamic therapy vs cryotherapy for multiple actinic keratoses on the extremities" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2008.08488.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2008" "volumen" => "158" "paginaInicial" => "994" "paginaFinal" => "999" "link" => array:1 [ …1] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0780" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer drug resistance: An evolving paradigm" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrc3599" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Cancer" "fecha" => "2013" "volumen" => "13" "paginaInicial" => "714" "paginaFinal" => "726" "link" => array:1 [ …1] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0785" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer cell resistance mechanisms: A mini review" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12094-014-1162-1" "Revista" => array:6 [ "tituloSerie" => "Clin Transl Oncol" "fecha" => "2014" "volumen" => "16" "paginaInicial" => "511" "paginaFinal" => "516" "link" => array:1 [ …1] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0790" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mechanisms of resistance to photodynamic therapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Curr Med Chem" "fecha" => "2011" "volumen" => "18" "paginaInicial" => "2486" "paginaFinal" => "2515" "link" => array:1 [ …1] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0795" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "What's new in dermato-oncology?" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0151-9638(11)70099-0" "Revista" => array:7 [ "tituloSerie" => "Ann Dermatol Venereol" "fecha" => "2011" "volumen" => "138" "numero" => "Suppl 4" "paginaInicial" => "S253" "paginaFinal" => "S262" "link" => array:1 [ …1] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0800" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2133.2011.10270.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2011" "volumen" => "165" "paginaInicial" => "144" "paginaFinal" => "151" "link" => array:1 [ …1] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0805" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/ng.192" "Revista" => array:6 [ "tituloSerie" => "Nat Genet" "fecha" => "2008" "volumen" => "40" "paginaInicial" => "1130" "paginaFinal" => "1135" "link" => array:1 [ …1] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0810" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Isolation and initial characterization of mouse tumor cells resistant to porphyrin-mediated photodynamic therapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cancer Res" "fecha" => "1991" "volumen" => "51" "paginaInicial" => "4243" "paginaFinal" => "4249" "link" => array:1 [ …1] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0815" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular aspects of cancer cell resistance to chemotherapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bcp.2013.02.017" "Revista" => array:6 [ "tituloSerie" => "Biochem Pharmacol" "fecha" => "2013" "volumen" => "85" "paginaInicial" => "1219" "paginaFinal" => "1226" "link" => array:1 [ …1] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0820" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methylene blue reverts multidrug resistance: Sensitivity of multidrug resistant cells to this dye and its photodynamic action" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cancer Lett" "fecha" => "2000" "volumen" => "151" "paginaInicial" => "161" "paginaFinal" => "167" "link" => array:1 [ …1] ] ] ] ] ] ] 42 => array:3 [ "identificador" => "bib0825" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of 5-aminolevulinic acid-mediated photodynamic therapy on MCF-7 and MCF-7/ADR cells" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/lsm.10246" "Revista" => array:6 [ "tituloSerie" => "Lasers Surg Med" "fecha" => "2004" "volumen" => "34" "paginaInicial" => "62" "paginaFinal" => "72" "link" => array:1 [ …1] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0830" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Photochemical activation of drugs for the treatment of therapy-resistant cancers" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1039/c5pp00029g" "Revista" => array:6 [ "tituloSerie" => "Photochem Photobiol Sci" "fecha" => "2015" "volumen" => "14" "paginaInicial" => "1465" "paginaFinal" => "1475" "link" => array:1 [ …1] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0835" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: Pharmacological, genetic, and clinical evidence" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10555-011-9306-z" "Revista" => array:6 [ "tituloSerie" => "Cancer Metastasis Rev" "fecha" => "2011" "volumen" => "30" "paginaInicial" => "343" "paginaFinal" => "361" "link" => array:1 [ …1] ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0840" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cyclooxygenases: Mediators of UV-induced skin cancer and potential targets for prevention" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/jid.2014.192" "Revista" => array:6 [ "tituloSerie" => "J Invest Dermatol" "fecha" => "2014" "volumen" => "134" "paginaInicial" => "2497" "paginaFinal" => "2502" "link" => array:1 [ …1] ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0845" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pbio.1001945" "Revista" => array:5 [ "tituloSerie" => "PLoS Biol" "fecha" => "2014" "volumen" => "12" "paginaInicial" => "e1001945" "link" => array:1 [ …1] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0850" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Autophagy, a major adaptation pathway shaping cancer cell death and anticancer immunity responses following photodynamic therapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1039/c4pp00466c" "Revista" => array:6 [ "tituloSerie" => "Photochem Photobiol Sci" "fecha" => "2015" "volumen" => "14" "paginaInicial" => "1410" "paginaFinal" => "1424" "link" => array:1 [ …1] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0855" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of cytoskeleton and adhesion proteins in the resistance to photodynamic therapy. Possible therapeutic interventions" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1039/c4pp00445k" "Revista" => array:6 [ "tituloSerie" => "Photochem Photobiol Sci" "fecha" => "2015" "volumen" => "14" "paginaInicial" => "1451" "paginaFinal" => "1464" "link" => array:1 [ …1] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0860" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor-generated nitric oxide as an antagonist of photodynamic therapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1039/c4pp00470a" "Revista" => array:6 [ "tituloSerie" => "Photochem Photobiol Sci" "fecha" => "2015" "volumen" => "14" "paginaInicial" => "1425" "paginaFinal" => "1432" "link" => array:1 [ …1] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0865" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.redox.2015.07.015" "Revista" => array:6 [ "tituloSerie" => "Redox Biol" "fecha" => "2015" "volumen" => "6" "paginaInicial" => "311" "paginaFinal" => "317" "link" => array:1 [ …1] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0870" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor cell lines resistant to ALA-mediated photodynamic therapy and possible tools to target surviving cells" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Oncol" "fecha" => "2006" "volumen" => "29" "paginaInicial" => "397" "paginaFinal" => "405" "link" => array:1 [ …1] ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0875" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "In vitro induction of PDT resistance in HT29, HT1376 and SK-N-MC cells by various photosensitizers" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Photochem Photobiol" "fecha" => "2001" "volumen" => "73" "paginaInicial" => "651" "paginaFinal" => "656" "link" => array:1 [ …1] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0880" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "PLoS One" "fecha" => "2014" "volumen" => "9" "paginaInicial" => "107158" ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0885" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Facial basal cell carcinomas recurring after photodynamic therapy: A retrospective analysis of histological subtypes" "autores" => array:1 [ 0 => array:2 [ …2] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000339335" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2012" "volumen" => "224" …3 ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0890" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methyl-aminolevulinic acid photodynamic therapy for actinic keratoses: A useful treatment or a risk factor? A retrospective study" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/09546634.2014.915004" "Revista" => array:6 [ …6] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0895" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oncogenic H-Ras and PI3<span class="elsevierStyleHsp" style=""></span>K signaling can inhibit E-cadherin-dependent apoptosis and promote cell survival after photodynamic therapy in mouse keratinocytes" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jcp.21652" "Revista" => array:7 [ …7] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0900" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Isolation and characterization of squamous carcinoma cells resistant to photodynamic therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jcb.23145" "Revista" => array:6 [ …6] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0905" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Protoporphyrin IX-dependent photodynamic production of endogenous ROS stimulates cell proliferation" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejcb.2011.12.001" "Revista" => array:6 [ …6] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0910" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ensayo clínico: la infiltración intralesional con metotrexato de forma neoadyuvante en la cirugía del queratoacantoma permite obtener mejores resultados estéticos y funcionales" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2011.03.013" "Revista" => array:6 [ …6] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0915" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intralesional methotrexate for the treatment of keratoacanthoma: Retrospective study and review of the Korean literature" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5021/ad.2014.26.2.172" "Revista" => array:6 [ …6] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0920" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neoadjuvant intralesional methotrexate before surgical treatment of invasive squamous cell carcinoma of the lower lip" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1524-4725.2012.02540.x" "Revista" => array:6 [ …6] ] ] ] ] ] 62 => array:3 [ "identificador" => "bib0925" "etiqueta" => "63" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intralesional methotrexate treatment for keratoacanthoma tumors: A retrospective study and review of the literature" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2006.12.017" "Revista" => array:6 [ …6] ] ] ] ] ] 63 => array:3 [ "identificador" => "bib0930" "etiqueta" => "64" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 64 => array:3 [ "identificador" => "bib0935" "etiqueta" => "65" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of keratoacanthoma: Is intralesional methotrexate an option?" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 65 => array:3 [ "identificador" => "bib0940" "etiqueta" => "66" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vismodegib and the Hedgehog pathway: A new treatment for basal cell carcinoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clinthera.2012.08.011" "Revista" => array:7 [ …7] ] ] ] ] ] 66 => array:3 [ "identificador" => "bib0945" "etiqueta" => "67" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "GDC-0449-a potent inhibitor of the hedgehog pathway" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bmcl.2009.08.049" "Revista" => array:6 [ …6] ] ] ] ] ] 67 => array:3 [ "identificador" => "bib0950" "etiqueta" => "68" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tratamiento del carcinoma basocelular invasivo o la vía del erizo" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 68 => array:3 [ "identificador" => "bib0955" "etiqueta" => "69" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Vertebrate Hedgehog signaling modulated by induction of a Hedgehog-binding protein" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/17611" "Revista" => array:6 [ …6] ] ] ] ] ] 69 => array:3 [ "identificador" => "bib0960" "etiqueta" => "70" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/13031" "Revista" => array:6 [ …6] ] ] ] ] ] 70 => array:3 [ "identificador" => "bib0965" "etiqueta" => "71" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Orchestrating ontogenesis: Variations on a theme by sonic hedgehog" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrg1969" "Revista" => array:6 [ …6] ] ] ] ] ] 71 => array:3 [ "identificador" => "bib0970" "etiqueta" => "72" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa0905360" "Revista" => array:6 [ …6] ] ] ] ] ] 72 => array:3 [ "identificador" => "bib0975" "etiqueta" => "73" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of vismodegib in advanced basal-cell carcinoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1113713" "Revista" => array:6 [ …6] ] ] ] ] ] 73 => array:3 [ "identificador" => "bib0980" "etiqueta" => "74" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa0902903" "Revista" => array:6 [ …6] ] ] ] ] ] 74 => array:3 [ "identificador" => "bib0985" "etiqueta" => "75" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1126/science.1179386" "Revista" => array:6 [ …6] ] ] ] ] ] 75 => array:3 [ "identificador" => "bib0990" "etiqueta" => "76" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/0008-5472.CAN-10-2876" "Revista" => array:6 [ …6] ] ] ] ] ] 76 => array:3 [ "identificador" => "bib0995" "etiqueta" => "77" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2014.08.001" "Revista" => array:6 [ …6] ] ] ] ] ] 77 => array:3 [ "identificador" => "bib1000" "etiqueta" => "78" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.molonc.2014.09.003" "Revista" => array:7 [ …7] ] ] ] ] ] 78 => array:3 [ "identificador" => "bib1005" "etiqueta" => "79" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ccell.2015.02.001" "Revista" => array:6 [ …6] ] ] ] ] ] 79 => array:3 [ "identificador" => "bib1010" "etiqueta" => "80" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Locally advanced and metastatic basal cell carcinoma: Molecular pathways, treatment options and new targeted therapies" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/14737140.2014.895326" "Revista" => array:6 [ …6] ] ] ] ] ] 80 => array:3 [ "identificador" => "bib1015" "etiqueta" => "81" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interfering with resistance to smoothened antagonists by inhibition of the PI3<span class="elsevierStyleHsp" style=""></span>K pathway in medulloblastoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 81 => array:3 [ "identificador" => "bib1020" "etiqueta" => "82" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ccr.2012.11.017" "Revista" => array:6 [ …6] ] ] ] ] ] 82 => array:3 [ "identificador" => "bib1025" "etiqueta" => "83" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2013.49.9525" "Revista" => array:6 [ …6] ] ] ] ] ] 83 => array:3 [ "identificador" => "bib1030" "etiqueta" => "84" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/emmm.201100201" "Revista" => array:6 [ …6] ] ] ] ] ] 84 => array:3 [ "identificador" => "bib1035" "etiqueta" => "85" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "GLI activation by atypical protein kinase C ι/λ regulates the growth of basal cell carcinomas" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nature11889" "Revista" => array:6 [ …6] ] ] ] ] ] 85 => array:3 [ "identificador" => "bib1040" "etiqueta" => "86" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Protein kinase A activation inhibits oncogenic sonic hedgehog signalling and suppresses basal cell carcinoma of the skin" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/exd.12016" "Revista" => array:6 [ …6] ] ] ] ] ] 86 => array:3 [ "identificador" => "bib1045" "etiqueta" => "87" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "RAS/MAPK activation drives resistance to Smo inhibition, metastasis and tumor evolution in Shh pathway-dependent tumors" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/0008-5472.CAN-14-2999-T" "Revista" => array:6 [ …6] ] ] ] ] ] 87 => array:3 [ "identificador" => "bib1050" "etiqueta" => "88" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Digging a hole under Hedgehog: Downstream inhibition as an emerging anticancer strategy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bbcan.2015.06.003" "Revista" => array:6 [ …6] ] ] ] ] ] 88 => array:3 [ "identificador" => "bib1055" "etiqueta" => "89" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1073/pnas.0609699104" "Revista" => array:6 [ …6] ] ] ] ] ] 89 => array:3 [ "identificador" => "bib1060" "etiqueta" => "90" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nm.3613" "Revista" => array:6 [ …6] ] ] ] ] ] 90 => array:3 [ "identificador" => "bib1065" "etiqueta" => "91" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1074/jbc.M114.595348" "Revista" => array:6 [ …6] ] ] ] ] ] 91 => array:3 [ "identificador" => "bib1070" "etiqueta" => "92" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Radiation-induced EGFR-signaling and control of DNA-damage repair" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/09553000701769970" "Revista" => array:6 [ …6] ] ] ] ] ] 92 => array:3 [ "identificador" => "bib1075" "etiqueta" => "93" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 93 => array:3 [ "identificador" => "bib1080" "etiqueta" => "94" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EGFR overexpression and radiation response in glioblastoma multiforme" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 94 => array:3 [ "identificador" => "bib1085" "etiqueta" => "95" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Growth factors and their receptors: New targets for prostate cancer therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 95 => array:3 [ "identificador" => "bib1090" "etiqueta" => "96" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The EGFR as a target for anticancer therapy–focus on cetuximab" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 96 => array:3 [ "identificador" => "bib1095" "etiqueta" => "97" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidermal growth factor receptor biology (IMCC225)" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 97 => array:3 [ "identificador" => "bib1100" "etiqueta" => "98" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The EGF receptor family as targets for cancer therapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/sj.onc.1204082" "Revista" => array:6 [ …6] ] ] ] ] ] 98 => array:3 [ "identificador" => "bib1105" "etiqueta" => "99" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.radonc.2011.05.035" "Revista" => array:6 [ …6] ] ] ] ] ] 99 => array:3 [ "identificador" => "bib1110" "etiqueta" => "100" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without EGFR amplification" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ijrobp.2011.02.043" "Revista" => array:6 [ …6] ] ] ] ] ] 100 => array:3 [ "identificador" => "bib1115" "etiqueta" => "101" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: Final results of a phase II multicenter study (abstract)" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ …4] ] ] ] ] ] 101 => array:3 [ "identificador" => "bib1120" "etiqueta" => "102" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2009.24.6116" "Revista" => array:6 [ …6] ] ] ] ] ] 102 => array:3 [ "identificador" => "bib1125" "etiqueta" => "103" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Understanding resistance to EGFR inhibitors impact on future treatment strategies" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nrclinonc.2010.97" "Revista" => array:6 [ …6] ] ] ] ] ] 103 => array:3 [ "identificador" => "bib1130" "etiqueta" => "104" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nature11156" "Revista" => array:6 [ …6] ] ] ] ] ] 104 => array:3 [ "identificador" => "bib1135" "etiqueta" => "105" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.radonc.2013.06.023" "Revista" => array:6 [ …6] ] ] ] ] ] 105 => array:3 [ "identificador" => "bib1140" "etiqueta" => "106" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nuclear EGFR contributes to acquired resistance to cetuximab" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/onc.2009.234" "Revista" => array:6 [ …6] ] ] ] ] ] 106 => array:3 [ "identificador" => "bib1145" "etiqueta" => "107" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.canlet.2010.04.006" "Revista" => array:6 [ …6] ] ] ] ] ] 107 => array:3 [ "identificador" => "bib1150" "etiqueta" => "108" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0012702" "Revista" => array:5 [ …5] ] ] ] ] ] 108 => array:3 [ "identificador" => "bib1155" "etiqueta" => "109" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/onc.2008.19" "Revista" => array:6 [ …6] ] ] ] ] ] 109 => array:3 [ "identificador" => "bib1160" "etiqueta" => "110" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo) radiation and survival in cervical cancer" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/1078-0432.CCR-09-1149" "Revista" => array:6 [ …6] ] ] ] ] ] 110 => array:3 [ "identificador" => "bib1165" "etiqueta" => "111" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1126/scitranslmed.3002442" "Revista" => array:5 [ …5] ] ] ] ] ] 111 => array:3 [ "identificador" => "bib1170" "etiqueta" => "112" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.radonc.2013.02.001" "Revista" => array:6 [ …6] ] ] ] ] ] 112 => array:3 [ "identificador" => "bib1175" "etiqueta" => "113" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.canlet.2011.12.012" "Revista" => array:6 [ …6] ] ] ] ] ] 113 => array:3 [ "identificador" => "bib1180" "etiqueta" => "114" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: A unifying concept in stress response biology" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1023/B:CANC.0000031769.14728.bc" "Revista" => array:6 [ …6] ] ] ] ] ] 114 => array:3 [ "identificador" => "bib1185" "etiqueta" => "115" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Taking treatment decisions in non-melanoma skin cancer-the place for topical photodynamic therapy (PDT)" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pdpdt.2009.12.004" "Revista" => array:6 [ …6] ] ] ] ] ] 115 => array:3 [ "identificador" => "bib1190" "etiqueta" => "116" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Three-year retrospective review of superficial radiotherapy for skin conditions in a Perth radiotherapy unit" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ …6] ] ] ] ] ] 116 => array:3 [ "identificador" => "bib1195" "etiqueta" => "117" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term recurrence rate of large and difficult to treat cutaneous squamous cell carcinomas after superficial radiotherapy" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000337027" "Revista" => array:6 [ …6] ] ] ] ] ] 117 => array:3 [ "identificador" => "bib1200" "etiqueta" => "118" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Utility of radiotherapy for treatment of basal cell carcinoma: A review" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.13253" "Revista" => array:6 [ …6] ] ] ] ] ] 118 => array:3 [ "identificador" => "bib1205" "etiqueta" => "119" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Squamous cell carcinoma of the skin: Epidemiology, classification, management, and novel trends" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ijd.12553" "Revista" => array:6 [ …6] ] ] ] ] ] 119 => array:3 [ "identificador" => "bib1210" "etiqueta" => "120" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interventions for non-metastatic squamous cell carcinoma of the skin: Systematic review and pooled analysis of observational studies" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ …5] ] ] ] ] ] 120 => array:3 [ "identificador" => "bib1215" "etiqueta" => "121" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inhibition of STAT -3 results in radiosensitization of human squamous cell carcinoma" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.radonc.2009.06.022" "Revista" => array:6 [ …6] ] ] ] ] ] 121 => array:3 [ "identificador" => "bib1220" "etiqueta" => "122" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacologic treatment options for advanced epithelial skin cancer" "autores" => array:1 [ …1] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/14656566.2015.1052743" "Revista" => array:6 [ …6] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010700000009/v1_201611010039/S1578219016302219/v1_201611010039/en/main.assets" "Apartado" => array:4 [ "identificador" => "6150" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010700000009/v1_201611010039/S1578219016302219/v1_201611010039/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219016302219?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 15 | 16 | 31 |
| 2024 Octubre | 98 | 45 | 143 |
| 2024 Septiembre | 88 | 45 | 133 |
| 2024 Agosto | 140 | 60 | 200 |
| 2024 Julio | 85 | 47 | 132 |
| 2024 Junio | 102 | 39 | 141 |
| 2024 Mayo | 85 | 40 | 125 |
| 2024 Abril | 95 | 36 | 131 |
| 2024 Marzo | 88 | 43 | 131 |
| 2024 Febrero | 82 | 34 | 116 |
| 2024 Enero | 56 | 35 | 91 |
| 2023 Diciembre | 56 | 15 | 71 |
| 2023 Noviembre | 65 | 30 | 95 |
| 2023 Octubre | 73 | 30 | 103 |
| 2023 Septiembre | 92 | 26 | 118 |
| 2023 Agosto | 49 | 18 | 67 |
| 2023 Julio | 59 | 29 | 88 |
| 2023 Junio | 53 | 23 | 76 |
| 2023 Mayo | 52 | 27 | 79 |
| 2023 Abril | 51 | 19 | 70 |
| 2023 Marzo | 61 | 20 | 81 |
| 2023 Febrero | 56 | 29 | 85 |
| 2023 Enero | 54 | 21 | 75 |
| 2022 Diciembre | 73 | 47 | 120 |
| 2022 Noviembre | 55 | 38 | 93 |
| 2022 Octubre | 50 | 27 | 77 |
| 2022 Septiembre | 54 | 39 | 93 |
| 2022 Agosto | 78 | 43 | 121 |
| 2022 Julio | 101 | 35 | 136 |
| 2022 Junio | 34 | 31 | 65 |
| 2022 Mayo | 74 | 39 | 113 |
| 2022 Abril | 43 | 24 | 67 |
| 2022 Marzo | 56 | 46 | 102 |
| 2022 Febrero | 67 | 31 | 98 |
| 2022 Enero | 68 | 21 | 89 |
| 2021 Diciembre | 46 | 42 | 88 |
| 2021 Noviembre | 59 | 52 | 111 |
| 2021 Octubre | 69 | 65 | 134 |
| 2021 Septiembre | 56 | 56 | 112 |
| 2021 Agosto | 52 | 33 | 85 |
| 2021 Julio | 37 | 30 | 67 |
| 2021 Junio | 56 | 34 | 90 |
| 2021 Mayo | 35 | 35 | 70 |
| 2021 Abril | 93 | 59 | 152 |
| 2021 Marzo | 80 | 34 | 114 |
| 2021 Febrero | 66 | 30 | 96 |
| 2021 Enero | 35 | 27 | 62 |
| 2020 Diciembre | 36 | 16 | 52 |
| 2020 Noviembre | 24 | 23 | 47 |
| 2020 Octubre | 39 | 16 | 55 |
| 2020 Septiembre | 34 | 19 | 53 |
| 2020 Agosto | 40 | 23 | 63 |
| 2020 Julio | 29 | 23 | 52 |
| 2020 Junio | 49 | 31 | 80 |
| 2020 Mayo | 40 | 16 | 56 |
| 2020 Abril | 33 | 15 | 48 |
| 2020 Marzo | 46 | 14 | 60 |
| 2020 Febrero | 7 | 0 | 7 |
| 2019 Diciembre | 4 | 0 | 4 |
| 2019 Septiembre | 4 | 0 | 4 |
| 2019 Junio | 2 | 0 | 2 |
| 2019 Mayo | 2 | 2 | 4 |
| 2019 Abril | 2 | 4 | 6 |
| 2019 Marzo | 7 | 0 | 7 |
| 2019 Enero | 8 | 0 | 8 |
| 2018 Diciembre | 4 | 0 | 4 |
| 2018 Noviembre | 3 | 0 | 3 |
| 2018 Octubre | 2 | 0 | 2 |
| 2018 Septiembre | 4 | 0 | 4 |
| 2018 Febrero | 33 | 12 | 45 |
| 2018 Enero | 56 | 20 | 76 |
| 2017 Diciembre | 64 | 18 | 82 |
| 2017 Noviembre | 46 | 20 | 66 |
| 2017 Octubre | 59 | 25 | 84 |
| 2017 Septiembre | 30 | 13 | 43 |
| 2017 Agosto | 40 | 13 | 53 |
| 2017 Julio | 42 | 15 | 57 |
| 2017 Junio | 42 | 24 | 66 |
| 2017 Mayo | 44 | 18 | 62 |
| 2017 Abril | 35 | 14 | 49 |
| 2017 Marzo | 35 | 29 | 64 |
| 2017 Febrero | 79 | 21 | 100 |
| 2017 Enero | 39 | 18 | 57 |
| 2016 Diciembre | 68 | 40 | 108 |
| 2016 Noviembre | 79 | 62 | 141 |
| 2016 Octubre | 8 | 20 | 28 |
Mostrar todo
